Target intelligence / Profile preview

ATP-binding cassette sub-family C member 8 (SUR1) (ABCC8)

Target
ABCC8
Molecular classification
ATP-binding cassette transporter, Ion channel subunit, Potassium channel regulator
01

Overview

The ATP-binding cassette sub-family C member 8 (ABCC8), commonly known as the Sulfonylurea receptor 1 (SUR1), is a critical regulatory subunit of the ATP-sensitive potassium (K_ATP) channel found in pancreatic beta cells (UniProt, 2024). This channel functions as a metabolic sensor, coupling the intracellular ATP/ADP ratio to the cell's membrane potential to regulate insulin secretion (PubMed, PMC2642993). When blood glucose levels rise, the resulting increase in ATP leads to the closure of the K_ATP channel via SUR1, triggering membrane depolarization, calcium influx, and subsequent insulin release (StatPearls, 2023). Mutations in the ABCC8 gene are a primary cause of glycemic disorders, including neonatal diabetes and congenital hyperinsulinism, highlighting its central role in glucose homeostasis (NIH, GeneReviews). Pharmacologically, SUR1 is the primary target for sulfonylureas and meglitinides, which promote insulin secretion by closing the channel to treat type 2 diabetes (PubChem, CID 3488). Conversely, potassium channel openers like diazoxide bind to SUR1 to maintain the channel in an open state, which is used to treat conditions of excessive insulin secretion (NCBI, NBK537154).

Other names
Sulfonylurea receptor 1SUR1ABC36HRINSMRP8PHHI
02

Mechanism of action

Sulfonylureas and meglitinides bind to the SUR1 subunit of the K_ATP channel to induce channel closure, which triggers membrane depolarization and subsequent insulin release; conversely, diazoxide binds to SUR1 to stabilize the channel in the open state, inhibiting insulin secretion.

03

Biological functions

Regulation of insulin secretionPotassium ion transportGlucose homeostasisMembrane potential regulationMetabolic sensing
04

Disease associations

Type 2 diabetes mellitusCongenital hyperinsulinismNeonatal diabetes mellitusHyperinsulinemic hypoglycemiaMaturity-onset diabetes of the young (MODY)
05

Safety considerations

HypoglycemiaWeight gainSecondary treatment failure (beta-cell exhaustion)Cardiovascular risks due to potential cross-reactivity with SUR2 subunits in cardiac and vascular smooth muscle
06

Interacting drugs

Glibenclamide (Glyburide)

7 more in the full profile.

07

Biomarkers

Blood glucose levelsC-peptide levelsABCC8 genetic variantsInsulin-to-glucose ratio

Beyond the preview

Go deeper on ATP-binding cassette sub-family C member 8 (SUR1) (ABCC8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-binding cassette sub-family C member 8 (SUR1) (ABCC8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call